Skip to main content
Home / Current Pharmaceutical Biotechnology, Volume 18, Number 11

Aerosol Drug Delivery Through High Flow Nasal Cannula

Buy Article:

$68.00 + tax (Refund Policy)

Author: Ari, Arzu

Source: Current Pharmaceutical Biotechnology, Volume 18, Number 11, 2017, pp. 877-882(6)

Publisher: Bentham Science Publishers

DOI: https://doi.org/10.2174/1389201019666171219104217

Background: High flow nasal cannula (HFNC) is widely utilized to support critically ill adults, pediatrics and neonates. Through the continuous delivery of oxygen at high flow rates that meet or exceed patients' inspiratory flow, HFNC improves oxygenation, respiratory rates, patient comfort, and tolerance during therapy. As HFNC becomes more widely employed, clinicians have started to consider aerosol drug delivery through HFNC.

Conclusion: Using HFNC along with nebulizers as a potential therapy in aerosol medicine is a new and innovative approach for aerosol drug delivery to patients with pulmonary diseases.

The purpose of this paper is to review current in vitro and in vivo studies on aerosol drug delivery through HFNC in adults and children.

Keywords: Aerosols; adults; high flow nasal cannula; nebulizers; neonates; pediatrics

Document Type: Review Article

Publication date: 01 September 2017

This article was made available online on 17 January 2018 as a Fast Track article with title: "Aerosol Drug Delivery Through High Flow Nasal Cannula".

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content